Deliver Your News to the World

Agilent Technologies, BIA Separations GmbH Sign Agreement Giving Agilent Access to BIA Separations’ Bio-Monolithic Technology


SANTA CLARA, Calif., and KLAGENFURT, Austria, May 2008

Agilent Technologies Inc. (NYSE: A) and BIA Separations GmbH today announced the signing of an agreement that gives Agilent access to BIA Separations’ bio-monolithic technology. Agilent plans to commercialize analytical HPLC bio-monolith columns with strong and weak ion-exchange phases and a Protein A phase. BIA Separations currently provides their preparative scale CIM(r) disk and process scale CIM(r) tube bio-monolithic products for purification and bioconversion of bio-molecules.

“Having access to the bio-monolithic technology allows Agilent to provide enabling solutions for the analytical separation of virus particles, plasmid DNA, antibodies and other macro bio-molecules,” said Helen Stimson, vice president and general manager of Agilent’s Global Columns and Supplies Solutions. “This technology, when applied at the analytical scale, will improve bio-drug characterization in development and allow QA/QC and process control labs to better monitor and characterize the production of biologics.”

BIA Separations’ bio-monolithic technology is a revolutionary chromatographic and bioconversion support based on a highly cross-linked porous monolithic polymer. Due to a well-defined pore-size distribution, the monolith provides excellent separation power and efficiency. The support is characterized by flow-independent, high-resolution separations and a flow-independent binding capacity. It can be operated at very high flow rates, significantly decreasing the separation time of large bio-molecules.

“The partnership between Agilent and BIA Separations will make the bio- monolithic technology available to the analytical bio-chromatography market and will allow BIA Separations to focus its marketing and sales activities on preparative and process scale bio-chromatography applications,” said Ales Strancar, BIA Separations managing director and co-inventor of CIM(r) monolithic column technology. “BIA Separations is currently offering enabling and cost-effective purification solutions for large bio-molecules and nano-particles like IgM, plasmid DNA, vaccines, viral vectors and phages at the industrial scale.”


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.